Financial Times:
Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis — Chief of Google's AI unit and Isomorphic Labs spells out targets following $3bn Eli Lilly-Novartis partnerships